logo
Plus   Neg
Share
Email

AstraZeneca : Lynparza Receives Positive EU CHMP Opinion

AstraZeneca (AZN.L,AZN) and Merck & Co. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of Lynparza (olaparib) tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.

Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.

The positive opinion is based on data from the randomised, open-label, Phase III OlympiAD trial, which tested Lynparza against the physician's choice of chemotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Luckin Coffee Inc., Starbucks Corp.'s biggest rival in China, filed for an Initial Public Offering in the U.S. In a filing with the Securities and Exchange Commission, the China-based coffee chain said it has applied for listing its American Depositary Shares or ADSs on the Nasdaq under the symbol "LK" and also set a placeholder amount of $100 million. Micro-blogging site Twitter Inc. (TWTR) Tuesday reported a surge in its first-quarter profit. Both earnings and revenues beat analysts' estimates, sending shares up by 6 percent in the pre-market trading. But, Twitter's average monthly active users or MAU figure declined from last year. Verizon Communications Inc. on Tuesday reported a nearly 11 percent increase in profit for the first quarter from last year on higher wireless revenues and flat expenses. Adjusted earnings per share for the quarter beat analysts' estimates, while revenues were in-line with expectations. Looking ahead, the company raised its adjusted earnings outlook for fiscal 2019.
Follow RTT